Vascular regeneration: a new mechanism of glucagon-like peptide-1 receptor agonist-mediated cardioprotection?

The article explores the vascular regenerative benefits of glucagon-like peptide-1 (GLP-1) receptor (GLP-1R) agonists, particularly focusing on semaglutide, in individuals with type 2 diabetes and high cardiovascular risk. Topics include the increase in vascular regenerative progenitor cell content associated with GLP-1R agonist treatment, the comparison with sodium-glucose cotransporter-2 (SGLT2) inhibitors, and the broader cardioprotective effects of GLP-1R agonists beyond weight loss.